A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Jun 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2021.
- 04 Jun 2019 Results assessing carfilzomib maintenance for 1 year in patients with newly diagnosed multiple myeloma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 03 May 2019 Results investigating carfilzomib administered on a weekly schedule in combination with melphalan and prednisone for transplant-ineligible patients with untreated multiple myeloma published in the Clinical Cancer Research